Table 1 Summary of the clinical outcomes of patients with metastatic liver or lung cancer treated with allogeneic γδ T cells

From: Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer

 

Patient number

Sex

Age (year)

(Diagnosis/phase)

Infusion time

Treatment

Times of γδ T cells treatment

Clinical response

PA date

Survival (month)

Liver cancer patients

1

507882

M

47

Low differentiated hepatocellular carcinoma (T4N0M1 IV stage)

2017.6–2018.3

γδ + IRE

7

PA

2019.10

28

2

507524

F

56

Hepatic tubular cell carcinoma (cT3N1M0 IVA stage)

2017.8–2017.10

γδ + I125

6

SD

Live

35

3

507590

M

66

Hepatocellular carcinoma (T3bN1M0 IV stage)

2017.7–2017.10

γδ

5

PA

2018.5

10

4

004701

M

66

Hepatocellular carcinoma of hepatobiliary duct (T2N0M0 II stage)

2017.8–2018.4

γδ + IRE

7

PA

2019.10

26

5

507770

M

31

Hepatocellular carcinoma of hepatobiliary duct (TxN1M1 IV stage)

2017.8–2018.4

γδ + I125

13

CR

Live

35

6

508940

M

48

Hepatocellular carcinoma of hepatobiliary duct (T4N0M1 IV stage)

2017.9–2017.12

γδ + IRE + CYRO

6

PA

2018.1

4

7

375046

M

29

Hepatocellular carcinoma (TxNXM0 IV stage)

2017.11–2018.4

γδ

5

PD

Live

31

8

509410

F

40

Hepatocellular carcinoma (pT4NxMx III stage)

2018.2–2018.5

γδ + IRE

6

PA

2019.6

16

Lung cancer patients

1

507937

M

68

Left lung adenocarcinoma (cT3NxM1 IV stage)

2017.5–2017.10

γδ + IRE + CYRO

6

PA

2018.12

19

2

507936

F

61

Left lung adenocarcinoma (pT3N2M1 IV stage)

2017.5–2018.4

γδ + CYRO

12

PA

2019.10

29

3

508259

F

65

Right lung cancer (cTxNxM1 IV stage)

2017.6–2017.12

γδ

6

PA

2018.9

15

4

508328

M

67

Right lung cancer (TXN2M1 IV stage)

2017.7–2017.12

γδ + I125

6

PA

2018.6

11

5

508144

F

55

Left lung small cell lung cancer (IV stage)

2017.4–2017.9

γδ

8

PA

2018.2

10

6

507497y

F

58　

Left lung squamous cell carcinoma (pT2N2M1 IV stage)

2017.9–2018.6

γδ + I125

8

PD

Live

33

7

509166

F

64

Left upper lung adenocarcinoma post operation (T4N0M0 III A stage)

2017.12–2018.2

γδ

6

PA

2019.9

21

8

509331

F

57

Right lung adenocarcinoma (T4N0M0)　

2017.12–2018.5

γδ

6

SD

Live

30

9

509459

F

47

Lung cancer (TXN2M1 IV stage)

2018.2–2018.4

γδ

7

PA

2018.5

3

10

508354

M

52

Right lung squamous carcinoma (T4N1M1 IV stage)

2017.4–1017.12

γδ + I125

6

PA

2018.12

20

  1. Patients with advanced liver or lung cancer were intravenously infused with NF cells (1–2 × 108 cells per treatment, purity >90%). Among the liver cancer patients, eight patients received ≥5 NF-cell infusions. These eight patients were followed until June 2020, and three of them were alive with current survival times of 30–35 months. The follow-up evaluation was performed according standards of the Response Evaluation Criteria in Solid Tumors (RECIST). Among the lung cancer patients, ten patients received ≥5 NF-cell infusions. These ten patients were followed until June 2020 as well. Nine of these ten patients survived ≥10 months, and two of them were still alive.
  2. M male, F female, PA passed away, PD progressive disease, CR complete response, SD stable disease
Back to article page